Search Results for "Devices"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Devices. Results 141 to 150 of 220 total matches.

In Brief: A New OTC Naloxone Nasal Spray (RiVive)

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
, AND COST — RiVive is supplied in packages containing two single-use nasal spray devices, each of which ...
The FDA has approved RiVive (Harm Reduction Therapeutics), a 3-mg naloxone nasal spray, as an over-the-counter (OTC) product for emergency treatment of opioid overdose. Two 4-mg naloxone nasal spray formulations, Narcan and one of its generics, were approved for OTC sale in 2023.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):47-8   doi:10.58347/tml.2024.1698d |  Show IntroductionHide Introduction

Eroxon — An OTC Gel for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
with nitrates.1-3 Alternatives for management of ED include vacuum erection devices, intraurethral ...
The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel (Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved OTC and topical treatment for erectile dysfunction. It is also available in the UK and the EU.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):181-2   doi:10.58347/tml.2024.1715c |  Show IntroductionHide Introduction

Antimicrobial Prophylaxis for Surgery

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
, Staphylococcus aureus, cefazolin2,3 2 g IV4,5 valve repairs, device implantation Staphylococcus epidermidis ...
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Med Lett Drugs Ther. 2016 May 23;58(1495):63-8 |  Show IntroductionHide Introduction

A Subdermal Progestin Implant For Long-Term Contraception

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 1991  (Issue 839)
daily; after one year, in one study, the device released about 30 to 35 micrograms daily, which ...
The Norplant System (Wyeth-Ayerst) for subdermal delivery of the synthetic progestin levonorgestrel was recently approved by the US Food and Drug Administration for use as a long-term contraceptive.
Med Lett Drugs Ther. 1991 Mar 8;33(839):17-8 |  Show IntroductionHide Introduction

Drugs for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025  (Issue 1719)
visual acuity in patients with dry AMD. The device uses three light-emitting diodes to generate light ...
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5   doi:10.58347/tml.2025.1719a |  Show IntroductionHide Introduction

Insect Venom Immunotherapy

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993  (Issue 900)
, epinephrine-containing devices (Epi-Pen and Epi-Pen Jr − Center; Ana-Kit − Hollister-Stier) are available ...
Systemic allergic reactions to insect stings can include generalized urticaria, bronchospasm, laryngeal edema, hypotension and death. About 1% to 3% of adults in the USA have had a systemic allergic reaction to an insect sting (RE Reisman, Med Clin North Am, 76:883, 1992; UR M ller, Monogr Allergy, 31:131, 1993).
Med Lett Drugs Ther. 1993 Jul 9;35(900):63-4 |  Show IntroductionHide Introduction

Surgical Treatment of Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Nov 12, 1993  (Issue 909)
with a permanent stimulating device, including 8 who had bilateral stimulation, almost all had total or at least ...
Interest in surgical treatment of Parkinson's disease has increased as the limitations of medical treatment have become apparent (Medical Letter, 35:31, 1993). Two approaches have been used. The first is transplantation of dopamine-producing cells into the patient's brain. The second is stereotactic surgery in areas of the brain that modify movement.
Med Lett Drugs Ther. 1993 Nov 12;35(909):103-4 |  Show IntroductionHide Introduction

Tizanidine for Spasticity

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997  (Issue 1004)
; these devices require meticulous care to avoid infection, and fatalities have occurred due to overdosage ...
Tizanidine (Zanaflex - Athena Neurosciences) has been approved by the US Food and Drug Administration for oral treatment of increased muscle tone associated with spasticity. It has been available in Europe and Japan for 12 years as a short-term muscle relaxant.
Med Lett Drugs Ther. 1997 Jul 4;39(1004):62-3 |  Show IntroductionHide Introduction

Intranasal Naloxone for Treatment of Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014  (Issue 1438)
as needed. Naloxone can be administered intranasally using a mucosal atomizer device. A syringe ...
The recent increase in deaths from heroin overdose in the US has led to renewed interest in the opioid antagonist naloxone, particularly in making it available as an intranasal spray to paramedics and possibly to relatives and close friends of heroin users. Intravenous (IV) administration is preferred, but peripheral venous access may be difficult to obtain in IV drug abusers, and exposure to their blood may be hazardous.
Med Lett Drugs Ther. 2014 Mar 17;56(1438):21-2 |  Show IntroductionHide Introduction

OTC Primatene Mist Returns

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019  (Issue 1564)
use and 1 spray before each subsequent inhalation). The device should be cleaned after each day ...
The FDA has approved over-the-counter (OTC) sale of inhaled epinephrine (Primatene Mist – Amphastar), a nonselective alpha and beta agonist, for temporary relief of mild symptoms of intermittent asthma in patients ≥12 years old who have been diagnosed with mild intermittent asthma by a healthcare professional. The original version of Primatene Mist, which was approved by the FDA in 1967, was removed from the market in 2011 because the metered-dose inhaler (MDI) contained ozone-depleting chlorofluorocarbon (CFC) propellants; the new MDI contains hydrofluoroalkane (HFA)...
Med Lett Drugs Ther. 2019 Jan 28;61(1564):9-10 |  Show IntroductionHide Introduction